drugset / Trial / NCT04387136

Intraoperative Sublingual Sufentanil for Acute Pain in the Ambulatory Surgery Center

NCT04387136

Phase 4 Completed 53 enrolled University of Minnesota
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to determine if a single dose of sublingual sufentanil given 15-30 minutes prior to wake up is efficacious at reducing recovery room time.

Timeline

Start
2020-10-14
Primary completion
2021-02-04
Completion
2021-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sufentanil Other / unclassified 30 ug Other

Indications

No indication recorded.